Investor Contact: Jeremy Friedman

Executive Vice President and Chief Financial Officer

978 570 6900

Jeremy.friedman@accellent.com

#### FOR IMMEDIATE RELEASE

### **Accellent Inc. Announces First Quarter 2012 Results**

Wilmington, MA (May 14, 2012) – Accellent Inc. (the "Company" or "Accellent"), a wholly owned subsidiary of Accellent Holdings Corp., today announced results for its fiscal first quarter ended March 31, 2012.

#### First Quarter 2012 Financial Results

Net sales increased 1.3% to \$131.6 million in the first quarter of 2012 compared with \$129.9 million in the first quarter of 2011. Income from operations was \$11.0 million in the first quarter of 2012, compared with \$13.0 million in the first quarter of 2011. Net loss was \$7.0 million in the first quarter of 2012, compared with a net loss of \$8.2 million in the first quarter of 2011.

Adjusted EBITDA for the first quarter of 2012 was \$23.0 million, or 17.5% of net sales, compared to Adjusted EBITDA of \$23.8 million, or 18.4% of net sales, in the first quarter of 2011.

"We returned to year over year top-line growth in the first quarter, despite a continued soft market," stated Donald Spence, President and CEO of Accellent. "Revenue increased 1.3% in the first quarter; however our profitability declined compared to last year. I remain optimistic that we are creating the necessary changes in our business to succeed both in today's challenging market and also in the long-term."

Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in the financial information accompanying this press release.

#### **Conference Call**

Donald Spence, President and Chief Executive Officer, and Jeremy A. Friedman, Executive Vice President and Chief Financial Officer, will discuss our first quarter financial results in a conference call scheduled for today, May 14, 2012 at 5 p.m. Eastern Standard Time. The teleconference can be accessed live on the Internet through the Investor Relations section of the Accellent website at <a href="www.accellent.com">www.accellent.com</a> or by calling (866) 804-6928 pass code 88571031. Please visit the website or dial in 10 to 15 minutes prior to the beginning of the call to download and install any necessary audio software. A replay of the conference call will be available via <a href="www.accellent.com">www.accellent.com</a> or by telephone at (888) 286-8010 pass code 35531841 until May 21, 2012.

#### **About Accellent**

Accellent Holdings Corp., through its wholly owned subsidiary Accellent, Inc., provides fully integrated outsourced manufacturing and engineering services to the medical device industry primarily in the cardiology, endoscopy and orthopedic markets. Accellent has broad capabilities in precision component fabrication, finished device assembly, complete supply chain management capabilities and engineering services. These capabilities enhance customers' speed to market and return on investment by enabling them to refocus internal resources more efficiently. For more information, please visit www.accellent.com.

## **Forward-Looking Statements**

This press release includes "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All statements included herein, other than statements of historical fact, may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the risk factors contained in the Company's Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission on March 29, 2012. All forward-looking statements are expressly qualified in their entirety by such risk factors.

## ACCELLENT INC. Unaudited Condensed Consolidated Statements of Operations (in thousands)

	<b>Three Months Ended</b>				
	March 31,	March 31, 2012			
	2011				
Net sales	\$ 129,889	\$ 131,578			
Cost of sales (exclusive of amortization)	98,318	100,967			
Gross profit	31,571	30,611			
Operating expenses:					
Selling, general and administrative expenses	14,112	15,050			
Research and development expenses	747	474			
Restructuring charges	-	353			
Gain on disposal of property and equipment	-	(1)			
Amortization of intangible assets	3,735	3,735			
Total operating expenses	18,594	19,611			
Income from operations	12,977	11,000			
Other (expense) income, net:					
Interest expense, net	(17,249)	(17,242)			
Other (expense) income, net	(1,934)	178			
Total other (expense) income, net	(19,183)	(17,064)			
Loss before income taxes	(6,206)	(6,064)			
Provision for income taxes	1,965	922			
Net loss	\$ (8,171)	\$ (6,986)			

## ACCELLENT INC. Unaudited Condensed Consolidated Balance Sheets (in thousands)

	December 31, 2011		, , , , , , , , , , , , , , , , , , ,		larch 31, 2012
Assets					
Current assets:					
Cash	\$	38,858		\$	35,149
Accounts receivable, net		54,763			62,023
Inventory		65,962			71,193
Prepaid expenses and other current assets	4,481				5,277
Total current assets		164,064			173,642
Property, plant and equipment, net		126,992			124,563
Goodwill		629,854			629,854
Other intangible assets, net		149,687			145,952
Deferred financing costs and other assets, net		16,825			16,195
Total assets	\$	1,087,422		\$	1,090,206
Liabilities and Stockholder's equity					
Current liabilities:					
Current portion of long-term debt	\$	22		\$	22
Accounts payable		22,580			27,142
Accrued expenses and other current liabilities		46,487			50,237
Total current liabilities		69,089			77,401
Long-term debt		712,967			713,042
Other long-term liabilities		38,466			39,085
Total liabilities		820,522			829,528
Stockholder's equity		266,900			260,678
Total liabilities and stockholder's equity	\$	1,087,422		\$	1,090,206

# ACCELLENT INC. Reconciliation of Net Loss to EBITDA to Adjusted EBITDA (in thousands)

		Three Months Ended			
	March 31, 2011		March 31, 2012		
Net loss	\$	(8,171)	\$	(6,986)	
Interest expense, net		17,249		17,242	
Provision for income taxes		1,965		922	
Depreciation and amortization		9,441		10,083	
EBITDA (1)	\$	20,484	\$	21,261	
Adjustments:					
Stock-based compensation – employees		248		40	
Stock-based compensation – non-employees		23		23	
Employee severance and relocation		335		814	
Restructuring charges		-		353	
Executive recruiting costs		221		-	
Plant closure costs and other		-		169	
Currency loss (gain)		2,020		(185)	
Gain on disposal of property and equipment		-		(1)	
Franchise and other taxes		190		205	
Management fees to stockholder		319		335	
Adjusted EBITDA (1)	\$	23,840	\$	23,014	

(1) EBITDA and Adjusted EBITDA presented in this press release are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. EBITDA and Adjusted EBITDA are not measurements of our financial performance under GAAP and should not be considered as alternatives to net income (loss) or any other performance measures derived in accordance with GAAP, or as an alternative to cash flow from operating activities as a measure of our liquidity.

EBITDA represents net income (loss) before net interest expense, provision for income taxes and depreciation and amortization. Adjusted EBITDA represents EBITDA further adjusted to give effect to certain non-cash items and other adjustments, all of which are defined in the indentures governing our debt. The adjustments include adjustments for restructuring charges and related plant closure costs, stock compensation charges, severance and relocation costs, executive recruiting costs, currency gains and losses, gains and losses on derivative instruments, gains and losses resulting from the disposal of property and equipment, certain non-income based taxes, losses on debt extinguishment, and management fees.

We believe that the presentation of EBITDA and Adjusted EBITDA is appropriate to provide as additional information for investors. We consider it an important supplemental measure of our performance and we believe that both are frequently used by securities analysts, investors and other interested parties in the evaluation of high yield issuers.